Studie SPARCL – the Stroke Prevention by Aggressive Reduction in Cholesterol Levels: commentary

Overview

The author in her paper reports on the objectives, results and outcomes of a prospective, randomised, placebo-controlled SPARCL study and she comments on the study. Patients aged over 18 with underwent ischemic or haemorrhagic CVD (cerebrovascular disease) were incorporated in the study. The aim of the study was to find out whether statins decrease the risk of CVD also in patients after CVD or a transient cerebral ischemic attack. The author observes that despite the limitations of the SPARCL study (with respect to the heterogeneity of CVD and the heterogeneity of patients in terms of the whole cardiovascular risk) its results and further analyses of sub-groups of the study will become a further enrichment of secondary prevention of primarily ischemic CVDs.

Keywords:
SPARCL –⁠ CMP –⁠ statin –⁠ LDL-cholesterol –⁠ TIA